Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 2
1989 2
1993 1
1994 3
1995 1
2002 2
2003 8
2004 6
2005 5
2006 11
2007 7
2008 17
2009 12
2010 15
2011 10
2012 20
2013 15
2014 7
2015 9
2016 13
2017 5
2018 14
2019 12
2020 9
2021 10
2022 4
2023 2
2024 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

214 results

Results by year

Filters applied: . Clear all
Page 1
Real-world evidence of osimertinib in Chinese patients with EGFR T790M-positive non-small cell lung cancer: a subgroup analysis from ASTRIS study.
Zhou Q, Zhang HL, Jiang LY, Shi YK, Chen Y, Yu JM, Zhou CC, He Y, Hu YP, Liang ZA, Pan YY, Zhuo WL, Song Y, Wu G, Chen GY, Lu Y, Zhang CY, Zhang YP, Cheng Y, Lu S, Wang CL, Zhou JY, Liu YP, He JX, Wang J, Wu YL. Zhou Q, et al. Among authors: shi yk. J Cancer Res Clin Oncol. 2023 Sep;149(12):10771-10780. doi: 10.1007/s00432-023-04923-8. Epub 2023 Jun 14. J Cancer Res Clin Oncol. 2023. PMID: 37316692 Free PMC article. Clinical Trial.
[Considerations for anti-cancer drug application by single arm trials].
Zhou M, Chen XY, Zhang H, Xia L, Tong X, Zou LM, Hao RM, Zhao X, Shi YK, Yang ZM. Zhou M, et al. Among authors: shi yk. Zhonghua Zhong Liu Za Zhi. 2018 Jan 23;40(1):58-62. doi: 10.3760/cma.j.issn.0253-3766.2018.01.011. Zhonghua Zhong Liu Za Zhi. 2018. PMID: 29365420 Review. Chinese.
[The development of biosimilars in oncology].
Jiang SY, Shi YK. Jiang SY, et al. Among authors: shi yk. Zhonghua Zhong Liu Za Zhi. 2017 Oct 23;39(10):721-725. doi: 10.3760/cma.j.issn.0253-3766.2017.10.001. Zhonghua Zhong Liu Za Zhi. 2017. PMID: 29061013 Chinese.
Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma.
Vitolo U, Trněný M, Belada D, Burke JM, Carella AM, Chua N, Abrisqueta P, Demeter J, Flinn I, Hong X, Kim WS, Pinto A, Shi YK, Tatsumi Y, Oestergaard MZ, Wenger M, Fingerle-Rowson G, Catalani O, Nielsen T, Martelli M, Sehn LH. Vitolo U, et al. Among authors: shi yk. J Clin Oncol. 2017 Nov 1;35(31):3529-3537. doi: 10.1200/JCO.2017.73.3402. Epub 2017 Aug 10. J Clin Oncol. 2017. PMID: 28796588 Clinical Trial.
214 results